Compare PLXS & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLXS | TMDX |
|---|---|---|
| Founded | 1979 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.9B |
| IPO Year | 1986 | 2019 |
| Metric | PLXS | TMDX |
|---|---|---|
| Price | $150.44 | $136.41 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 10 |
| Target Price | ★ $157.50 | $133.00 |
| AVG Volume (30 Days) | 164.5K | ★ 835.5K |
| Earning Date | 01-21-2026 | 10-29-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 56.11 | ★ 170.70 |
| EPS | ★ 6.26 | 2.54 |
| Revenue | ★ $4,032,966,000.00 | $566,354,000.00 |
| Revenue This Year | $10.99 | $38.84 |
| Revenue Next Year | $7.02 | $20.43 |
| P/E Ratio | ★ $24.02 | $53.83 |
| Revenue Growth | 1.82 | ★ 41.20 |
| 52 Week Low | $103.43 | $55.00 |
| 52 Week High | $172.89 | $156.00 |
| Indicator | PLXS | TMDX |
|---|---|---|
| Relative Strength Index (RSI) | 60.30 | 54.31 |
| Support Level | $141.26 | $133.50 |
| Resistance Level | $151.86 | $156.00 |
| Average True Range (ATR) | 5.09 | 8.50 |
| MACD | 1.22 | 0.41 |
| Stochastic Oscillator | 88.05 | 55.98 |
Plexus Corp designs, manufactures, and services complex products in demanding regulatory environments, supporting life-saving medical devices, mission-critical aerospace and defense products, industrial automation systems, and semiconductor capital equipment. Its integrated lifecycle solutions span design and development, supply chain solutions, new product introduction, manufacturing, and sustaining services for market and disruptive companies in the Aerospace/Defense, Healthcare/Life Sciences, and Industrial sectors. The Company operates through three reportable segments: AMER, APAC, and EMEA, with the majority of revenue from the APAC segment.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.